Braf/mek inhibitors

Braf/mek inhibitors decrease tumor size in humans.

“MAPK/ERK pathway, which is activated by somatic BRAF V600E mutations in PCP, has been successfully targeted with BRAF/MEK inhibitors, demonstrating significant efficacy in the majority of treated PCP patients”

Reviewpapillary craniopharyngioma

Pharmacological Treatment for Adamantinomatous Craniopharyngioma

Current oncology reports·16 Dec 2025